Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,087 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,087 shares of the firm’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $12.80, for a total value of $52,313.60. Following the sale, the insider directly owned 76,751 shares in the company, valued at approximately $982,412.80. This represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Nurix Therapeutics Trading Up 9.2%

Shares of NRIX stock opened at $12.78 on Friday. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56. The stock’s 50-day moving average price is $9.67 and its 200-day moving average price is $10.61. The stock has a market capitalization of $982.53 million, a price-to-earnings ratio of -4.30 and a beta of 2.33.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The firm had revenue of $7.89 million during the quarter, compared to the consensus estimate of $16.06 million. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. increased its stake in Nurix Therapeutics by 11.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock worth $14,391,000 after acquiring an additional 165,841 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Nurix Therapeutics during the third quarter valued at approximately $203,000. Nikko Asset Management Americas Inc. boosted its position in shares of Nurix Therapeutics by 83.8% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock valued at $15,796,000 after buying an additional 633,304 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the period. Finally, Vestal Point Capital LP boosted its position in shares of Nurix Therapeutics by 77.7% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock valued at $22,780,000 after buying an additional 874,448 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Nurix Therapeutics in a report on Wednesday, October 22nd. Oppenheimer reduced their target price on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, October 10th. HC Wainwright reduced their target price on Nurix Therapeutics from $33.00 to $28.00 and set a “buy” rating on the stock in a report on Monday. BTIG Research reduced their target price on Nurix Therapeutics from $35.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, October 23rd. Finally, UBS Group dropped their price target on Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.73.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.